Breast Cancer on the Run in October: (Day 5) NSABP: Research on Steroids
October 5: NSABP: RESEARCH ON STEROIDS
In the world of breast cancer it would be hard to highlight an organization or institution more responsible for the modern treatment of breast cancer than the National Surgical Adjuvant Breast Project (NSABP). It was established in the late fifties under the auspices of the National Cancer Institute (NCI) and has been a major force in the breast cancer world since.
Large scale, collaborative projects with appropriate controls represents the apex of clinical research. Breast cancer is a common disease lending itself, if folks are well organized, to a treasure trove of information offering insight into treatment, outcomes, and the behavior of the disease.
Among the NSABP’s more striking findings include establishing the efficacy of breast preservation treatment, the role of adjuvant chemotherapy as a weapon after surgery to increase survival, and the use of Tamoxifen as a chemo preventive agent. These only scratch the surface.
According to NSABP literature, over 100,000 women have been drawn into their clinical trials from over 1000 health care organizations (hospitals, large oncology practices, and HMOs). 5000 health care professionals from nurses to administrators have and are participating in their work.
With their large date base, questions can be asked and answered. Innovations and new ideas can be tested.
Large quantities of trusted and valid information expands our knowledge base. From knowledge comes advancement in our understanding of breast cancer and its treatment. The breast cancer world and breast cancer patients had been well served by the NSABP.